These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The additional effects of acipimox to simvastatin in the treatment of combined hyperlipidaemia. Hoogerbrugge N; Jansen H; De Heide L; Zillikens MC; Deckers JW; Birkenhäger JC J Intern Med; 1998 May; 243(5):151-6. PubMed ID: 9651568 [TBL] [Abstract][Full Text] [Related]
3. The additional effects of acipimox to simvastatin in the treatment of combined hyperlipidaemia. Hoogerbrugge N; Jansen H; De Heide L; Zillikens MC; Deckers JW; Birkenhäger JC J Intern Med; 1997 Feb; 241(2):151-5. PubMed ID: 9077372 [TBL] [Abstract][Full Text] [Related]
4. [Treatment of primary hyperlipidemia with 5-methylpyrazinecarboxylic acid (acipimox)]. Quintão EC; de Castilho LN Arq Bras Cardiol; 1985 Jan; 44(1):37-40. PubMed ID: 4062591 [No Abstract] [Full Text] [Related]
5. [Acipimox (Olbetam) as a secondary hypolipemic agent in combined hypertriglyceridemia and hyperlipidemia]. Yeshurun D; Hamood H; Morad N; Naschitz J Harefuah; 2000 Apr; 138(8):650-3, 710. PubMed ID: 10883206 [TBL] [Abstract][Full Text] [Related]
6. Safety, tolerability and efficacy of acipimox in type II hyperlipidaemia. Barlow CW; Soicher ER; Jankelow D; Myburgh DP S Afr Med J; 1990 May; 77(10):504-5. PubMed ID: 2343347 [TBL] [Abstract][Full Text] [Related]
7. Resolution of nicotinic acid-induced acanthosis nigricans by substitution of an analogue (acipimox) in a patient with type V hyperlipidaemia. Coates P; Shuttleworth D; Rees A Br J Dermatol; 1992 Apr; 126(4):412-4. PubMed ID: 1571266 [No Abstract] [Full Text] [Related]
8. Comparative study of acipimox and pravastatin in patients with combined hyperlipidemia. Fogari R; Marasi G; Vanasia A; Zoppi A; Lusardi P; Preti P Int J Clin Pharmacol Ther; 1997 Feb; 35(2):61-4. PubMed ID: 9147709 [TBL] [Abstract][Full Text] [Related]
9. A comparison of acipimox and nicotinic acid in type 2b hyperlipidaemia. O'Kane MJ; Trinick TR; Tynan MB; Trimble ER; Nicholls DP Br J Clin Pharmacol; 1992 Apr; 33(4):451-3. PubMed ID: 1576071 [TBL] [Abstract][Full Text] [Related]
10. [Pharmacologic treatment of dyslipidemias: Analysis of initiation recommendations and drug selection]. Davidoff P Rev Med Chil; 1991 Dec; 119(12):1423-32. PubMed ID: 9723101 [TBL] [Abstract][Full Text] [Related]
14. [Pharmacology of hypolipidemic agents]. Féry F; Balasse EO Rev Med Brux; 1997 Feb; 18(1):26-31. PubMed ID: 9132914 [TBL] [Abstract][Full Text] [Related]
15. Treatment of hyperlipidaemia with acipimox. Lintott CJ; Scott RS; Bremer JM Curr Med Res Opin; 1989; 11(6):374-9. PubMed ID: 2707049 [TBL] [Abstract][Full Text] [Related]
16. [Acipimox treatment of hyperlipidemia type II]. Noseda G; Fragiacomo C; Cairoli R Schweiz Med Wochenschr; 1982 Dec; 112(49):1790-1. PubMed ID: 6758114 [TBL] [Abstract][Full Text] [Related]
17. Nicotinic acid in the treatment of hyperlipidaemia. Drexel H Fundam Clin Pharmacol; 2007 Nov; 21 Suppl 2():5-6. PubMed ID: 18001312 [TBL] [Abstract][Full Text] [Related]
18. Acipimox in the treatment of patients with hyperlipidaemia: a double blind trial. Ball MJ; Vella M; Rechlass JP; Jones DB; Stirling C; Mann JI; Galton D Eur J Clin Pharmacol; 1986; 31(2):201-4. PubMed ID: 3803417 [TBL] [Abstract][Full Text] [Related]
19. Management of hyperlipidaemia: postscript. Sum CF; Tan CE; Chew LS Singapore Med J; 1995 Oct; 36(5):538. PubMed ID: 8882543 [No Abstract] [Full Text] [Related]
20. Effect of the antilipolytic nicotinic acid analogue acipimox on whole-body and skeletal muscle glucose metabolism in patients with non-insulin-dependent diabetes mellitus. Vaag A; Skött P; Damsbo P; Gall MA; Richter EA; Beck-Nielsen H J Clin Invest; 1991 Oct; 88(4):1282-90. PubMed ID: 1918378 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]